{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:44:48Z","timestamp":1772858688196,"version":"3.50.1"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T00:00:00Z","timestamp":1700611200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The influence of body composition on the effectiveness of immune checkpoint inhibitors (ICIs) in patients with melanoma is still uncertain in clinical practice. Therefore, the objective of this study was to examine the potential association between body composition and clinical outcomes in patients with melanoma undergoing ICIs treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic literature search was performed across several databases, including PubMed, Embase, Cochrane Library and Google Scholar, to gather relevant studies. The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS), assessed by hazard ratios (HR). Secondary outcomes, such as adverse events (AE), were evaluated using odds ratios (OR).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This meta-analysis comprised ten articles involving a total of 1,283 patients. Systemic analysis of all collected evidence revealed that body composition, including low skeletal muscle index (SMI) (OS: HR = 1.66, 95% CI = 1.13-2.43, p = 0.010; PFS: HR = 1.28, 95% CI = 1.06-1.55, p = 0.009), high subcutaneous adipose tissue density (SMD) (OS: HR = 1.93, 95% CI = 1.09-3.44, p = 0.025; PFS: HR = 1.31, 95% CI = 1.06-1.63, p = 0.012), and sarcopenia (OS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022; PFS: HR = 1.25, 95% CI = 1.03-1.51, p = 0.022), were significantly associated with OS and PFS in melanoma patients treated with ICIs. However, these markers did not show a significant association with treatment-related adverse events. Interestingly, no significant correlation was found between visceral fat index (VFI) (OS: HR = 0.71, 95% CI = 0.29-1.76, p = 0.462; PFS: HR = 0.98, 95% CI = 0.93-1.02, p = 0.274) and OS or PFS in melanoma patients under ICIs treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Body composition was found to be associated with decreased treatment response and lower long-term efficacy in patients with melanoma undergoing immune checkpoint inhibitor (ICI) therapy. However, it is important to note that body composition did not appear to contribute to increased incidence of adverse events in these patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1261202","type":"journal-article","created":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:57:19Z","timestamp":1700755039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Prognostic value of body composition on survival outcomes in melanoma patients receiving immunotherapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Tianrui","family":"Kuang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhendong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weixing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.04.026","article-title":"Circulating tumor cells in stage IV melanoma patients","volume":"227","author":"Hall","year":"2018","journal-title":"J Am Coll Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.956533","article-title":"The association between antibiotic use and outcomes of HCC patients treated with immune checkpoint inhibitors","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00307-1","article-title":"PD-L1 expression as a potential predictive biomarker","volume":"16","author":"Fusi","year":"2015","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1152\/jappl.2000.89.1.104","article-title":"Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content","volume":"89","author":"Goodpaster","year":"2000","journal-title":"J Appl Physiol (1985)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumours: A meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41598-020-58498-2","article-title":"Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1\/PD-L1 checkpoint inhibitors: a multicenter real-life study","volume":"10","author":"Cortellini","year":"2020","journal-title":"Sci Rep"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics10050310","article-title":"Clinical impact of sarcopenia and inflammatory\/nutritional markers in patients with unresectable metastatic urothelial carcinoma treated with pembrolizumab","volume":"10","author":"Shimizu","year":"2020","journal-title":"Diagnostics (Basel)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14740\/wjon1225","article-title":"Sarcopenia and visceral adiposity did not affect efficacy of immune-checkpoint inhibitor monotherapy for pretreated patients with advanced non-small cell lung cancer","volume":"11","author":"Minami","year":"2020","journal-title":"World J Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106907","article-title":"Sarcopenia affects clinical efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients: A systematic review and meta-analysis","volume":"88","author":"Wang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx271","article-title":"Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy","volume":"28","author":"Bozzetti","year":"2017","journal-title":"Ann Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: revised European consensus on definition and diagnosis","volume":"48","author":"Cruz-Jentoft","year":"2019","journal-title":"Age Ageing"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"350","author":"Shamseer","year":"2015","journal-title":"Bmj"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000001509","article-title":"Circulating leptin and adiponectin levels in patients with pancreatic cancer","volume":"134","author":"Yuan","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.12538","article-title":"Body composition is prognostic and predictive of ipilimumab activity in metastatic melanoma","volume":"11","author":"Chu","year":"2020","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.431","article-title":"The impact of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma","volume":"116","author":"Daly","year":"2017","journal-title":"Br J Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.1038\/s41598-019-46189-6","article-title":"Macroangiopathy is a positive predictive factor for response to immunotherapy","volume":"9","author":"Deike-Hofmann","year":"2019","journal-title":"Sci Rep"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11122314","article-title":"Deep learning-based body composition analysis predicts outcome in melanoma patients treated with immune checkpoint inhibitors","volume":"11","author":"Faron","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-017-0464-x","article-title":"Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients","volume":"35","author":"Heidelberger","year":"2017","journal-title":"Invest New Drugs"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14528","article-title":"Higher BMI, but not sarcopenia, is associated with pembrolizumab-related toxicity in patients with advanced melanoma","volume":"40","author":"Hu","year":"2020","journal-title":"Anticancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005226","article-title":"Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2021.01.009","article-title":"Myosteatosis is prognostic in metastatic melanoma treated with nivolumab","volume":"42","author":"Youn","year":"2021","journal-title":"Clin Nutr ESPEN"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000821","article-title":"Impact of body composition on outcomes from anti-PD1 +\/- anti-CTLA-4 treatment in melanoma","volume":"8","author":"Young","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/nri.2017.108","article-title":"The diverse functions of the PD1 inhibitory pathway","volume":"18","author":"Sharpe","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4333","article-title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","volume":"23","author":"Zehir","year":"2017","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgp127","article-title":"Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability","volume":"30","author":"Colotta","year":"2009","journal-title":"Carcinogenesis"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0751","article-title":"Combined effect of sarcopenia and systemic inflammation on survival in patients with advanced stage cancer treated with immunotherapy","volume":"25","author":"Bilen","year":"2020","journal-title":"Oncologist"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2017.12.023","article-title":"Chronic inflammation and sarcopenia: A regenerative cell therapy perspective","volume":"103","author":"Chhetri","year":"2018","journal-title":"Exp Gerontol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2015.10.006","article-title":"Interactions between adipose tissue and the immune system in health and malnutrition","volume":"27","author":"Wensveen","year":"2015","journal-title":"Semin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01173","article-title":"Adipose tissue-resident immune cells in obesity and type 2 diabetes","volume":"10","author":"Lu","year":"2019","journal-title":"Front Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29881","article-title":"Obesity induces a phenotypic switch in adipose tissue macrophage polarization","volume":"117","author":"Lumeng","year":"2007","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.08.010","article-title":"Metabolic dysfunction drives a mechanistically distinct proinflammatory phenotype in adipose tissue macrophages","volume":"20","author":"Kratz","year":"2014","journal-title":"Cell Metab"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1964","article-title":"CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity","volume":"15","author":"Nishimura","year":"2009","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0908771107","article-title":"Induction of regulatory T cells decreases adipose inflammation and alleviates insulin resistance in ob\/ob mice","volume":"107","author":"Ilan","year":"2010","journal-title":"Proc Natl Acad Sci U.S.A."}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1261202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T15:57:23Z","timestamp":1700755043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1261202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,22]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2023.1261202"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1261202","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,22]]},"article-number":"1261202"}}